AC Immune SA (ACIU) FinancialsACIUFinancialAC Immune SA

Evaluating the bottom line, AC Immune SA maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 7.89%, while the net margin is 12.40%. These profitability ratios, combined with a Return on Equity (ROE) of -78.53%, provide a clear picture of how effectively ACIU converts its operational activities into shareholder value.

In the context of the broader market, ACIU competes directly with industry leaders such as PYXS and MGNX. With a market capitalization of $247.57M, it holds a significant position in the sector. When comparing efficiency, ACIU's gross margin of 100.00% stands against PYXS's N/A and MGNX's N/A. Such benchmarking helps identify whether AC Immune SA is trading at a premium or discount relative to its financial performance.

AC Immune has shown a significant recovery in its financials, with a Q2 net income of $2.4 million and a gross margin consistently at 100% over the past quarters. This indicates strong profitability potential as the company continues to grow its revenue.